Luminex (LMNX), Bio-Rad (BIO) Enter MAGPIX Sales, Distribution Agreement
Tweet
Share
E-mailGet Alerts LMNX Hot Sheet
Join SI Premium – FREE
Luminex Corporation (NASDAQ: LMNX) today announced that it has extended its global sales and distribution agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO) to 2023. In addition, Luminex has granted Bio-Rad global sales and distribution rights for Luminex's award-winning MAGPIX multiplexing instrument.
As part of the agreement, Bio-Rad will now offer the full range of Luminex's xMAP® systems including the MAGPIX system, a compact, flexible instrument that simultaneously detects up to 50 different analytes (including proteins and nucleic acids) on a single sample quickly, accurately and reproducibly.
As part of the agreement, Bio-Rad will now offer the full range of Luminex's xMAP® systems including the MAGPIX system, a compact, flexible instrument that simultaneously detects up to 50 different analytes (including proteins and nucleic acids) on a single sample quickly, accurately and reproducibly.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- enVVeno Medical (NVNO) files $100M mixed shelf
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
